Poorly Soluble and Poorly Permeable Drugs valued at $145 billion represent significant reformulation and market opportunities - KTVN Channel 2 - Reno Tahoe News Weather, Video -

Poorly Soluble and Poorly Permeable Drugs valued at $145 billion represent significant reformulation and market opportunities

  • Wendy Damonte's Health Watch ReportsMore>>

  • Request Remind Me 2 Kit

    Request a Remind Me 2 Kit

         More >>
  • AP: Probe Exposes Flaws Behind HealthCare.gov Rollout

    AP: Probe Exposes Flaws Behind HealthCare.gov Rollout

    Wednesday, July 30 2014 1:19 PM EDT2014-07-30 17:19:15 GMT
    Officials tell The Associated Press that a nonpartisan investigative report concludes that management failures by the Obama administration set the stage for the computer problems that paralyzed the HealthCare.gov website last fall.More >>
    Officials tell The Associated Press that a nonpartisan investigative report concludes that management failures by the Obama administration set the stage for the computer problems that paralyzed the HealthCare.gov website last fall.More >>
  • Health Officials Report Whooping Cough Cases Up in Nevada

    Health Officials Report Whooping Cough Cases Up in Nevada

    Tuesday, July 29 2014 7:01 PM EDT2014-07-29 23:01:35 GMT
    Nevada health officials say the Silver State has seen a rise in pertussis cases over recent years. As of last month, Nevada has had 60 cases of pertussis reported, more than this time last year, hinting towards another year of elevated pertussis cases in the state.More >>
    Nevada health officials say the Silver State has seen a rise in pertussis cases over recent years. As of last month, Nevada has had 60 cases of pertussis reported, more than this time last year, hinting towards another year of elevated pertussis cases in the state.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Technology Catalysts International

FALLS CHURCH, Va., July 11, 2014 /PRNewswire/ -- Poor bioavailability is a major reason for compounds to fail in preclinical development.  Technology Catalysts International (TCI), a leading global pharmaceutical consulting firm, has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds.  Due to the complex nature of a multitude of existing as well as newly-discovered active ingredients, solubility and bioavailability problems are inherent in the pharmaceutical industry causing major delays in drug development.  Fortuitously, several novel drug delivery technologies can now be deployed to address solubility and bioavailability issues.

Technology Catalysts' newly released report on "Poorly Soluble and Poorly Permeable Drugs", identifies 30 poorly soluble drugs with low bioavailability recently launched in the US.  TCI believes these drugs represent a huge business opportunity for specialty pharmaceutical, drug delivery, as well as generic companies using technologies that TCI has identified.  TCI estimates the current sales of BCS Class IV oral solid dose drugs to be in excess of $145 billion.

In a recent conversation with TCI, Jane Nichols, Director of Business Development for Nanocopoeia, Inc., an innovative provider of nanosized API particles for enhancing drug solubility, stated "demand for novel drug delivery technologies and materials to improve solubility and permeability of drugs is only going to rapidly increase over time and Nanocopoeia, with our focus on particle based therapeutics, is poised to play a strong role in this field."

TCI's report describes in detail vital techniques such as solid dispersion, hot-melt extrusion, nanotechnology, and complexation to enhance solubility of many molecules.  Permeability through the gastrointestinal tract is a rate limiting step for delivering macromolecules and very polar compounds.  Examples of technologies specifically designed to solve these problems that are covered in the report include natural transporter systems, enzyme inhibition, and bioadhesion.  Also discussed in the report is the use of gamma scintigraphy in combination with smart pills that has enabled a better understanding of the permeation of drugs in the GI tract. 

The report provides key information such as water solubility, bioavailability, and 2012-2013 annual sales.  Over 80 detailed descriptions of licensing and business opportunities for enhancing solubility and permeability discussed in the report provide a comprehensive understanding as well as vital solutions for overcoming these issues.

To download a complimentary excerpt of this report, go to:

http://www.technology-catalysts.com/pdf/psd7_bro.pdf

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research.  The company specializes in technology licensing, technology assessment, and business intelligence.  With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has office in Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Contact:

Ajay Rastogi, Vice President
Technology Catalysts International
Telephone (703) 531-0257
arastogi@technology-catalysts.com 
http://www.technology-catalysts.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Sarkes Tarzian, Inc. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.